Work

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study

Year: 2024

Type: article

Study design: Clinical Trial

Source: Arthritis & Rheumatology

DOI: 10.1002/art.43059

Authors: Thomas Dörner, Simon J. Bowman, Robert Fox, Xavier Mariette, Athena Papas, Thomas Grader‐Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze‐Koops, Robert J. Moots, Guido Junge, Janice Woznicki, Monika Sopala, Alexandre Avrameas, Wen‐Lin Luo, Wolfgang Hueber

Institutions: Charité - Universitätsmedizin Berlin, University Hospitals Birmingham NHS Foundation Trust, Scripps Memorial Hospital, Université Paris-Saclay, Bicêtre Hospital, Tufts University, Johns Hopkins University, Johns Hopkins Medicine, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Instituto Português de Reumatologia, University of Udine, Ludwig-Maximilians-Universität München, Edge Hill University, Aintree University Hospital, Novartis (Switzerland), Novartis (United States)

Language: English

Topic: Salivary Gland Disorders and Functions

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404493375

FWCI: 6.575

Cites: 32

Cited by: 28

Related to: 10